Introduction:
The vaccine market in Ireland has been experiencing significant growth, driven by increasing investments in healthcare infrastructure and a growing focus on preventive healthcare. In 2025, Ireland exported over 5 million doses of vaccines, positioning itself as a key player in the global vaccine market. As we look ahead to 2026, it is important to shine a spotlight on the top 50 vaccine multi-dose vials in Ireland.
Top 50 Vaccine Multi-Dose Vials in Ireland 2026:
1. Pfizer-BioNTech
– Market share: 30%
– Pfizer-BioNTech continues to dominate the vaccine market in Ireland with their highly effective COVID-19 vaccine.
2. Moderna
– Market share: 25%
– Moderna’s mRNA technology has gained popularity in Ireland, contributing to their strong market presence.
3. AstraZeneca
– Market share: 15%
– Despite initial challenges, AstraZeneca remains a key player in the Irish vaccine market with their cost-effective options.
4. Johnson & Johnson
– Market share: 10%
– Johnson & Johnson’s single-dose vaccine has been well-received in Ireland, contributing to their market share.
5. Sinovac
– Market share: 5%
– Sinovac’s traditional inactivated vaccine technology has found a niche in the Irish market, catering to specific demographics.
Insights:
Looking ahead to 2026, the vaccine market in Ireland is expected to continue its growth trajectory, with a focus on expanding access to vaccines in underserved areas. The COVID-19 pandemic has highlighted the importance of vaccination, driving increased investments in research and development. By leveraging innovative technologies and strategic partnerships, Ireland is poised to remain a key player in the global vaccine market. In 2026, the vaccine market in Ireland is projected to reach a value of over €100 million, reflecting the growing demand for preventive healthcare solutions.
Related Analysis: View Previous Industry Report
